- Medicenna (MDNA) unveils novel bifunctional superkines at the Cytokine-Based Cancer Immunotherapies Summit
- The presentation will happen at 2:25 pm ET
- The oral presentation, titled “Designer Cytokines,” will be given by Dr. Merchant
- Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines
- Medicenna Therapeutics Corp. (MDNA) is up 1.24 per cent and is trading at C$4.88 at 12:33 pm ET
Medicenna Therapeutics Corp. (MDNA) has an upcoming oral presentation of preclinical data on Medicenna’s Superkine platform programs.
On March 25, 2021, the presentation will happen at 2:25 pm ET at the virtual Cytokine-Based Cancer Immunotherapies Summit.
The presentation will feature preclinical data on MDNA11, a long-acting IL-2 Superkine that preferentially binds the IL-2 beta receptor (IL-2Rβ) on immune cells, as well as an overview of Medicenna’s Bi-functional Super Kine Immuno Therapies (BiSKITs™) program, including engineered interleukins designed to target immunologically “cold” tumours.
“Immunosuppressive tumour microenvironments (TMEs) often limit the efficacy of checkpoint inhibitors, highlighting an unmet need for new therapeutic agents that can induce an anti-cancer immune response and overcome immunotherapy resistance mechanisms,” said Fahar Merchant, Ph.D., President and CEO of Medicenna.
“New data show that MDNA11 monotherapy or when combined with anti-PD-1 therapy stimulated potent immune responses in preclinical tumour models highlighting the potential of our Superkine platform to address this need,” added Merchant.
The oral presentation, titled “Designer Cytokines,” will be given by Dr. Merchant today, March 25, 2021, at 2:25 pm ET. Dr. Merchant will also participate in a live Q&A session at 3:05 pm ET today.
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines to treat a broad range of cancers.
Medicenna’s long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity.
Therefore, it preferentially stimulates cancer-killing effector T cells and NK cells when compared to competing for IL-2 programs.
Medicenna Therapeutics Corp. (MDNA) is up 1.24 per cent and is trading at C$4.88 at 12:33 pm ET.